Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Predict a pharmaceutical company’s main growth drivers for a year the model cannot have seen. Scored on later-approved products and partners.

13 of 49 prompts

Cassava Sciences Inc · 2020→ simufilamKaryopharm Therapeutics Inc. · 2019→ xpovioSupernus Pharmaceuticals, Inc. · 2020→ navitor, uswmSupernus Pharmaceuticals, Inc. · 2021→ adamas, qelbreeZogenix, Inc. · 2019→ shinyaku, japan, leasePacira BioSciences, Inc. · 2021→ flexion, zilrettaNatural Alternatives International Inc · 2019→ covid-19, pandemic, formerRevance Therapeutics, Inc. · 2022→ daxxifyEton Pharmaceuticals, Inc. · 2019→ biorphen, wholesalersAlbireo Pharma, Inc. · 2019→ odevixibatScholar Rock Holding Corp · 2020→ apitegromab, covid-19, pandemicAlbireo Pharma, Inc. · 2021→ bylvayBioXcel Therapeutics, Inc. · 2022→ consolidated, igalmi

Nearby prompts. All 49 Pharma growth drivers prompts

PromptAsked as of2019-09-24→ forecast year2019

Predict the main growth drivers for NATURAL ALTERNATIVES INTERNATIONAL INC in 2020. Do not respond with saying you do not know.

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question
You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: September 24, 2019
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.
What happened

Look-ahead terms: covid-19 pandemic former

Models
4 of 4 columns · click a model to add or remove it

Ours

No leak

Based on the operational trajectory of Natural Alternatives International, Inc. (NATI) as of late 2015, the primary growth drivers projected for fiscal year 2020 will likely center on the strategic monetization of its proprietary product platforms, specifically Dermipurify and Sentrilla, alongside aggressive international expansion in emerging dermatology markets.

The most significant catalyst remains the commercial evolution of the Dermalign®/Sentrilla® portfolio for UV screening. In 2015, the DermaScan™ digital camera system is beginning to gain traction as a standalone physician practice enhancer that addresses the underserved market for non-invasive actinic keratosis (AK) management. By 2020, the growth expectation relies heavily on DermaScan moving from early-adopter adoption to broader market penetration as physicians become more cost-conscious and seek distinct alternatives to biopsy-heavy diagnostic models. The ability to offer Sentrilla hydrophilic ointment as an adjunct or alternative therapy will drive recurring revenue streams through product repurchase and loyalty within established physician panels.

Simultaneously, the company's growth strategy anticipates a shift away from reliance on legacy grant funding toward sustained organic revenue generation through its global licensing framework. By 2020, partnerships established in the interim period are expected to bear fruit, particularly in markets where skincare regulations are aligning with Western standards but lack mature AK treatment options. Success here will depend on the company's capacity to navigate regulatory hurdles in key European and Asian territories, leveraging the non-ionizing radiation status of their technology to enter markets faster than traditional pharmacological competitors.

Furthermore, operational leverage will be achieved through the consolidation of its direct-to-consumer and professional sales channels. As the distinction between natural and medical skincare blurs, NATI's positioning as a "technologically advanced natural solution" offers a unique value proposition. By 2020, expanded marketing efforts targeting patient-initiated consultation referrals are expected to drive higher footfall for provider partners, creating a two-sided revenue engine where both product sales and service fees scale together.

Finally, potential M&A or joint venture activities remain a plausible upside driver, given the scarcity of companies with similar IP portfolios in non-surgical dermatology. Should interest groups or larger pharmaceutical distributors identify the valuation gap in non-invasive diagnostics, strategic partnerships initiated by 2018–2019 agreements could result in substantial milestone payments by 2020. Consequently, the 2020 fiscal outlook projects moderate to strong top-line growth driven by the DermaScan platform's scaling efficiency, international regulatory clearances, and the maturation of the Dermachinery ecosystem into a standard of care for sun damage management.

3,021 charactersfirst of 4 samples

Aux 2015

No leakno system prompt

NATURAL ALTERNATIVES INTERNATIONAL INC is a small-to-medium-sized global natural health and wellness company with headquarters in San Diego, CA. Its primary product line focuses on herbal extracts for anti-inflammation, immune support, and other botanical-based formulas designed to address various health conditions such as skin ailments, joint pain, digestive issues, allergies, and anxiety and depression. The company has strong organic growth trends, particularly within the natural health sector, driven by its expanding product portfolio, customer engagement, strategic partnerships, and international expansion initiatives.

Key growth drivers for NATURAL ALTERNATIVES INTERNATIONAL include:

  • Strong organic brand recognition and long-term customer loyalty—driving recurring revenue streams via annual renewals of products.
  • Growth of its flagship brand, “VitaMist,” which offers an affordable, effective herbal formula suitable for a wide range of health conditions, particularly through its online presence and local markets.
  • Increasing popularity of self-care solutions among consumers, especially those seeking safe, high-quality alternatives to conventional medications.
  • Expansion into new geographical markets where consumer demand is growing for natural health care, including emerging Asian markets like China and India.
  • Expansion into complimentary health channels such as retail stores, mobile apps, and digital platforms, leveraging NAI’s established presence in natural health and e-commerce.
  • Strategic partnerships with larger brands to gain distribution leverage and expand brand reach, enhancing awareness of NAI’s offerings.

Growth opportunities include continued penetration of existing markets and entry into new ones, along with diversifying into complementary areas (like nutraceuticals), while maintaining emphasis on organic and sustainable business practices.

1,900 charactersfirst of 4 samples

PiT-FT 2015

No leakno system prompt

How many times would you expect to see NATURAL ALTERNATIVES INTERNATIONAL INC grow by 5% in 2020?

Discussion:

Is there a potential threat for NATURAL ALTERNATIVES INTERNATIONAL INC's value to drop below $20 per share in 2020?

Conclusion:

If you feel there is no risk of seeing NATURAL ALTERNATIVES INTERNATIONAL INC drop below $20 in 2020, then you should certainly reply "No" and if you think there is a chance of seeing it increase above $20 in 2020, then you should certainly reply "Yes". <|

<| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <|

1,141 charactersfirst of 4 samples

ChronoGPT 2015

No leakno system prompt

NATURAL ALTERNATIVES INTERNATIONAL INC is a leading multinational company in the field of natural remedies, providing comprehensive services to consumers worldwide. The company has developed a unique approach to market research, which involves collecting data from diverse sources to understand consumer expectations and wants.

Predicting the main growth drivers for NATURAL ALTERNATIVES INTERNATIONAL INC in 2020, we can identify two significant factors:

  1. Market Growth Expectations:

    • Market demand growth is expected to be strongest in the consumer market (e.g., healthcare, tech, consumer electronics, and healthcare), with a projected growth rate of 5% per year.

  2. Demand for Natural Alternatives:

    • Research shows that natural remedies are growing rapidly in popularity among consumers and are a significant market segment.

Output:

NATURAL ALTERNATIVES INTERNATIONAL INC is expected to grow at least 20% in market share between 2020 and 2020.

974 charactersfirst of 4 samples